Kezar Life Sciences, Inc. (NASDAQ:KZR) Given Consensus Recommendation of “Reduce” by Brokerages

Kezar Life Sciences, Inc. (NASDAQ:KZR) has earned a consensus recommendation of “Reduce” from the six analysts that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation and four have assigned a hold recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $6.00.

A number of research firms have issued reports on KZR. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kezar Life Sciences in a report on Monday, December 22nd. Wall Street Zen raised shares of Kezar Life Sciences to a “hold” rating in a report on Saturday, November 22nd.

Institutional Trading of Kezar Life Sciences

Several large investors have recently added to or reduced their stakes in KZR. Landscape Capital Management L.L.C. acquired a new position in shares of Kezar Life Sciences in the third quarter valued at about $51,000. Torno Capital LLC acquired a new stake in shares of Kezar Life Sciences during the fourth quarter worth about $126,000. Nano Cap New Millennium Growth Fund L P purchased a new stake in Kezar Life Sciences in the fourth quarter valued at approximately $157,000. Woodline Partners LP purchased a new stake in Kezar Life Sciences in the first quarter valued at approximately $125,000. Finally, Dimensional Fund Advisors LP increased its holdings in Kezar Life Sciences by 14.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 26,543 shares of the company’s stock worth $167,000 after buying an additional 3,312 shares during the period. Hedge funds and other institutional investors own 67.90% of the company’s stock.

Kezar Life Sciences Stock Performance

KZR opened at $6.85 on Monday. Kezar Life Sciences has a 52-week low of $3.53 and a 52-week high of $7.45. The company has a quick ratio of 7.06, a current ratio of 7.07 and a debt-to-equity ratio of 0.02. The company has a market cap of $50.14 million, a P/E ratio of -0.81 and a beta of 0.53. The firm’s 50-day moving average price is $6.45 and its 200-day moving average price is $5.73.

Kezar Life Sciences Company Profile

Kezar Life Sciences is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapies that modulate the innate immune system. The company’s research centers on selective inhibition of the immunoproteasome, a key protein complex involved in antigen processing and secretion of inflammatory cytokines. By targeting this pathway, Kezar aims to address unmet medical needs in autoimmune and inflammatory diseases with high specificity and a favorable safety profile.

The company’s lead development candidate, KZR-616, is a selective immunoproteasome inhibitor being evaluated in multiple clinical trials for autoimmune conditions such as systemic lupus erythematosus, lupus nephritis, polymyositis and dermatomyositis.